Technology Appraisal Committee Meeting (Committee [A])

Minutes: [Confirmed]

Date and Time: 14 March 2018

Venue: National Institute for Health and Care Excellence
       10 Spring Gardens
       London SW1A 2BU

Present: 1. Chair Jane Adam  Present for all notes
         2. Professor Iain Squire  Present for all notes
         3. Dr Jeremy Braybrooke  Present for all notes
         4. Mr John Cairns  Present for all notes
         5. Dr Justin Daniels  Present for all notes
         6. Mr David Evans  Present for all notes
         7. Dr Rachel Hobson  Present for all notes
         8. Professor John McMurray  Present for all notes
         9. Mrs Sarah Parry  Present for all notes
        10. Dr Mohit Sharma  Present for all notes
        11. Mr Stephen Sharp  Present for all notes
        12. Dr Brian Shine  Present for all notes
        13. Dr John Watkins  Present for all notes
        14. Professor Olivia Wu  Present for all notes

In attendance:

Meindert Boysen  Programme Director, National Institute for Health and Care Excellence  Present for all notes

Janet Robertson  Associate Director, National Institute for Health and Care Excellence  Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
<th>Present for all notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Feist</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td></td>
</tr>
<tr>
<td>Marcia Miller</td>
<td>Technology Appraisal Administrator, National Institute for Health and Care Excellence</td>
<td></td>
</tr>
<tr>
<td>Marcela Hassova</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td></td>
</tr>
<tr>
<td>Zoe Charles</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td></td>
</tr>
</tbody>
</table>

**Non-public attendees:**

- **Evidence Review Group**
  - Dr Steve Edwards: Health Economist BMJ-TAG
  - Tracey Jhita: Health Economist, BMJ-TAG
  - Charlotta Karner: Health Economist BMJ-TAG
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy [ID1041]

2. The Chair informed the Committee of the non-public observers at this meeting: Ana Uribe Echverry, Adam Storrow and Irina Voicechovskaja.

3. Apologies were received from Mr Adrian Griffin, Dr Steve Edwards, Dr Paul Robinson, Dr Graham Ash, Dr Minal Bakhai, Dr Rita Faria, Ms Ellen Rule and Ms Pamela Rees

Notes from the last meeting

4. The minutes of the last meeting were agreed

Appraisal of Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy [ID1041]

Part 1 – Open session

5. The Chair welcomed the invited experts: to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Tesaro to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Jane Adam, Professor Ian Squire, Dr Jeremy Braybrooke, Mr John Cairns, Dr Justin Daniels, Mr David Evans, Dr Rachel Hobson, Mrs Sarah Parry, Dr Mohit Sharma, Mr Stephen Sharp, Dr Brian Shine, Dr John Watkins and Professor Olivia Wu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy

7.2. Professor John McMurray declared a non-personal non-specific financial interest as he is chair of the committee leading a trial funded by AstraZeneca using a diabetes drug in patients with heart failure. In addition he is part of the committee leading 3 concurrent trials funded by them using an anaemia correction drug in patients with chronic kidney disease. All payments are made to Glasgow University.
7.2.1 It was agreed that this declaration would not prevent Professor John McMurray from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy.

9. The Chair asked the ERG team to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy.

10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

13. The Chair then thanked the evidence and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy.
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

17. Tuesday 17 April 2018, 10am at the National Institute for Health and Care Excellence, 10 Spring Garden, SW1A 2BU.